Skip to content
The Kids Research Institute Australia logo

Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial

Due to their anatomical locations, optic pathway gliomas (OPGs) can rarely be cured by resection. Given the importance of preserving visual function, we analyzed radiological and visual acuity (VA) outcomes for the type II RAF inhibitor tovorafenib in the OPG subgroup of the phase 2 FIREFLY-1 trial.

Citation:
Nysom K, Kilburn LB, Leary SES, Landi DB, …….. Gottardo NG, Hassall T, ……. et al. Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial. Neuro Oncol. 2025;27(5):1341-1355 

Keywords:
BRAF; FIREFLY-1; optic pathway glioma; tovorafenib; visual acuity; neoplasms; pediatrics

Abstract:
Due to their anatomical locations, optic pathway gliomas (OPGs) can rarely be cured by resection. Given the importance of preserving visual function, we analyzed radiological and visual acuity (VA) outcomes for the type II RAF inhibitor tovorafenib in the OPG subgroup of the phase 2 FIREFLY-1 trial.